Search Within

Jae Hong Park

Formats
  1. Meeting Abstract (222)
  2. Journal Article (132)
  3. Review (18)
  4. Research Letter (7)
  5. Editorial (3)
  6. Guidelines (3)
  7. Book Section (2)
  8. Correspondence (2)
Groups
  1. Adult Leukemia (389)
  2. Center for Hematologic Malignancies (389)
  3. Department of Medicine (389)
  4. Hematologic Malignancies, Division of (389)
  5. GSK Faculty (188)
  6. Hematology-Oncology Fellows (157)

More Groups

People
  1. Renier Brentjens (105)
  2. Isabelle Riviere (85)
  3. Maria Palomba (85)
  4. Michel Sadelain (84)
  5. Martin Tallman (81)
  6. Miguel-Angel Perales (73)

More People

Years
  1. 2025 (37)
  2. 2024 (38)
  3. 2023 (38)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (24)

More Years

Publications
  1. Blood (148)
  2. Journal of Clinical Oncology (31)
  3. Blood Advances (15)
  4. British Journal of Haematology (9)
  5. Haematologica (9)
  6. Leukemia and Lymphoma (9)

More Publications

Publishers
  1. American Society of Hematology (163)
  2. Elsevier Inc. (35)
  3. American Society of Clinical Oncology (33)
  4. Nature Publishing Group (32)
  5. Taylor & Francis Group (12)
  6. American Association for Cancer Research (10)

More Publishers

Results (389)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Context specific effects of the BRAFV600E mutation on hematopoiesis identifies novel models of BRAF mutant hematopoietic disorders
    Meeting Abstract

    Kim, E.; Chung, S. S.; Park, J. H.; Chung, Y. R.; Lito, P.; Feldstein, J.; Hu, W. H.; Beguilin, W.; Monette, S.; Duy, C.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • A systemic xenograft model of Waldenstrom's macroglobulinemia demonstrates the potent anti-tumor effect of second generation CD19 directed chimeric antigen receptor modified T cells in this disease
    Meeting Abstract

    Smith, E. L.; Palomba, M. L.; Park, J. H.; Brentjens, R. J.
    Blood (2014)

    Fulltext@MSK | Save
  • Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y. J.; Wang, X. Y.; Purdon, T. J.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A comprehensive clinical next generation sequencing-based assay can impact hematopathologic diagnosis in a significant subset of patients with hematologic malignancies
    Meeting Abstract

    Pichardo, J. D.; Feldstein, J. T.; Arcila, M.; Batlevi, C.; Zelenetz, A. D.; Moskowitz, C. H.; Horwitz, S. M.; Tallman, M. S.; Stein, E. M.; Klimek, V. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Vemurafenib has potent antitumor activity in patients with relapsed/refractory BRAF mutant hairy cell leukemia
    Meeting Abstract

    Park, J. H.; Chung, S. S.; Chung, Y. R.; Won, H.; Kim, E.; Saven, A.; Wadleigh, M.; Stone, R. M.; Barrientos, J. C.; Rai, K. R.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase I trial of targeted alpha-particle therapy using actinium-225 (Ac-225)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML)
    Meeting Abstract

    Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Douer, D.; Estey, E. H.; Kantarjian, H. M.; Wahl, R. L.; Earle, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genomic analysis of serial samples from CLL patients identifies clonal events associated with disease progression
    Meeting Abstract

    Gardner, J. R.; Nahas, M.; He, J.; Aumann, S.; Gonen, M.; Patel, M.; Knapp, K. M.; Palomba, M. L.; Yelensky, R.; Donahue, A. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen for the treatment of pediatric relapsed B cell ALL
    Meeting Abstract

    Curran, K. J.; Riviere, I.; Kobos, R.; Kernan, N. A.; Boulad, F.; Prockop, S. E.; Scaradavou, A.; Renaud, T. M.; Shukla, N.; Steinherz, P. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase I trial of autologous Cd19-targeted car-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated cll
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Bartido, S.; Sadelain, M.; Brentjens, R. J.
    Haematologica (2014)

    Fulltext@MSK | Save